EUVIMEDEUVIMED entdecken
Open Access

Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes

Hangqi Luo, Christopher W Anderson, Xin Li, Yinsheng Lu, Marie Hoareau, Qinzhe Xing, Saba Fooladi, Yufeng Liu, Zhen Xu, Jinkyu Park, Meghan E Fallon, Jordan Thomas und 6 weitere

Acta Biomaterialia · 2026-02 · 211 · 92-103

DOI: 10.1016/j.actbio.2025.06.055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-02. Verfasst von Hangqi Luo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, U.S. Department of Defense, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single ventricle congenital heart defects (SVCHDs) are life-threatening defects that can lead to severe circulation issues and increased stress on the heart. Without prompt treatment, these defects can prove fatal in infancy. Fontan surgery is a conventional treatment for SVCHDs, which reroutes oxygen-poor blood directly to the lungs, bypassing the non-functioning ventricle. This procedure, however, can lead to circulation inefficiencies due to the absence of a natural, functional ventricle to pump blood to the pulmonary circulation. To address this issue, our team previously developed a tissue-engineered pulsatile conduit (TEPC) by wrapping engineered heart tissues (EHTs) derived from human induced pluripotent stem cell-derived cardiomyocytes (hiPSCCMs) around decellularized human umbilical artery (dHUA). This conduit has demonstrated the ability to produce a luminal pressure of 0.68 mmHg from spontaneous beating, which under 2 Hz electrical stimulation, increases to 0.83 mmHg. This offers a promising modular TEPC design that has the potential to provide active pumping function to the pulmonary circulation. We have since significantly optimized our approach by providing the conduit with electrical pacing training and an additional layer of EHT. These two enhancements have achieved markedly greater contractile productivity, where the spontaneous pressure generation reached 0.96 mmHg and the stimulated luminal pressure generation attained 1.87 mmHg with 2 Hz pacing. Our studies thus underscore the effectiveness of these TEPC design modifications, marking significant progress in the ongoing effort to improve treatments for patients with SVCHDs. STATEMENT OF SIGNIFICANCE: Single ventricle congenital heart defects (SVCHDs) are a life-threatening disorder, leading to severe circulation issues and heart failure. The Fontan procedure reroutes blood to the lung but lacks active pumping required for efficient circulation, often causing long-term complications. To address this challenge, we developed a tissue-engineered pulsatile conduit (TEPC) using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and decellularized human umbilical artery (dHUA) scaffolds. Our optimized design, with electrical pacing and enhanced engineered heart tissue (EHT) approaches, significantly increased luminal pressure development (up to 1.87 mmHg at 2 Hz frequency), offering a promising solution to improve outcomes for SVCHD patients.

Schlagwörter

Stichwörter der Autor:innen

CardiomyocytesEngineered heart tissueHuman induced pluripotent stem cellsTissue-engineered pulsatile conduit

Autor:innen und Institutionen

  • Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, United States; Yale Stem Cell Center, New Haven, CT 06520, United St…
  • Department of Biomedical Engineering, Yale University, New Haven, CT 06510, United States.
  • Department of Pathology, Yale University, New Haven, CT 06520, United States; Department of Surgery, Yale University, New Haven, CT 06520, United States.
  • Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, United States; Department of Pediatrics, Yale School of Medicine, Ne…
  • Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, United States; Department of Biomedical Engineering, Yale University…

Förderung

  • NHLBI NIH HHS
  • U.S. Department of Defense
  • National Institutes of Health
  • American Heart Association Inc

Zitieren

APA

Luo, H., Anderson, C. W., Li, X., Lu, Y., Hoareau, M., Xing, Q., Fooladi, S., Liu, Y., Xu, Z., Park, J., Fallon, M. E., Thomas, J., Gruber, P. J., Elder, R. W., Mak, M., Riaz, M., Campbell, S. G., & Qyang, Y. (2026). Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes. Acta Biomaterialia, 211, 92-103. https://doi.org/10.1016/j.actbio.2025.06.055

Vancouver

Luo H, Anderson CW, Li X, Lu Y, Hoareau M, Xing Q, et al. Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes. Acta Biomaterialia. 2026;211:92-103. doi:10.1016/j.actbio.2025.06.055

BibTeX
@article{Luo2026,
  author = {Luo, Hangqi and Anderson, Christopher W and Li, Xin and Lu, Yinsheng and Hoareau, Marie and Xing, Qinzhe and Fooladi, Saba and Liu, Yufeng and Xu, Zhen and Park, Jinkyu and Fallon, Meghan E and Thomas, Jordan and Gruber, Peter J and Elder, Robert W and Mak, Michael and Riaz, Muhammad and Campbell, Stuart G and Qyang, Yibing},
  title = {Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {211},
  pages = {92--103},
  doi = {10.1016/j.actbio.2025.06.055}
}
Kostenlos starten →